Chemours (NYSE: CC) CEO gets 169,538-share stock award and tax withholding

Rhea-AI Filing Summary

Chemours Chief Executive Officer Denise Dignam reported equity compensation changes. She received a grant of 169,538 shares of common stock at $0.00 per share, in the form of restricted stock units scheduled to vest in three equal annual installments beginning on March 1, 2027. To satisfy tax obligations on vesting RSUs and related dividend equivalent units, 22,220 shares were automatically withheld at $18.24 per share; the company notes no shares were sold in the market. Following these transactions, she directly holds 335,313.8721 shares, including RSUs and dividend equivalent units.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Dignam Denise

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	169,538	$0.00	--
Tax Withholding	Common Stock	22,220	$18.24	$405K

Holdings After Transaction: Common Stock — 335,313.872 shares (Direct)

Footnotes (1)

1. Shares automatically withheld to satisfy tax obligations on vesting restricted stock units ("RSUs") and dividend equivalent units. Transactions are exempt from Section 16(b) pursuant to Rule 16b-3. No shares were sold. RSU award scheduled to vest in three equal annual installments beginning on March 1, 2027. Includes directly owned shares, RSUs and dividend equivalent units.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dignam Denise

(Last) (First) (Middle)

C/O THE CHEMOURS COMPANY

1007 MARKET STREET

(Street)

WILMINGTON DE 19801

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Chemours Co [ CC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/01/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/01/2026		F		22,220(1)	D	$18.24	165,775.8721	D
Common Stock	03/02/2026		A		169,538(2)	A	$0	335,313.8721(3)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares automatically withheld to satisfy tax obligations on vesting restricted stock units ("RSUs") and dividend equivalent units. Transactions are exempt from Section 16(b) pursuant to Rule 16b-3. No shares were sold.

2. RSU award scheduled to vest in three equal annual installments beginning on March 1, 2027.

3. Includes directly owned shares, RSUs and dividend equivalent units.

	/s/ Eric Stein, Attorney-in-Fact	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Chemours (CC) CEO Denise Dignam report?

Denise Dignam reported receiving a grant of 169,538 Chemours common shares at no cost as restricted stock units. She also had 22,220 shares automatically withheld at $18.24 per share to cover tax obligations on vesting RSUs and dividend equivalent units.

Were any Chemours (CC) shares sold by the CEO in this Form 4?

No open-market sale occurred. 22,220 Chemours shares were automatically withheld to satisfy tax obligations on vesting restricted stock units and dividend equivalent units. The filing explicitly states these transactions involved tax withholding and that no shares were sold.

What is the size and vesting schedule of the Chemours (CC) CEO’s new stock award?

The CEO received a restricted stock unit award covering 169,538 Chemours common shares. According to the filing, this RSU award is scheduled to vest in three equal annual installments, beginning on March 1, 2027, providing a multi-year equity incentive structure.

How many Chemours (CC) shares does the CEO hold after these transactions?

After the reported transactions, the CEO directly holds 335,313.8721 Chemours shares. The filing specifies this figure includes directly owned shares, restricted stock units, and associated dividend equivalent units, reflecting her total direct equity-based interest in the company.

Why were 22,220 Chemours (CC) shares withheld in the CEO’s Form 4 filing?

22,220 Chemours shares were automatically withheld to satisfy tax obligations arising from vesting restricted stock units and dividend equivalent units. The filing describes this as a tax-withholding disposition under code F, exempt under Rule 16b-3, and clarifies that no shares were sold.